Biohit Oyj - Total number of voting rights and capital

Increased number of Biohit shares entered into trade register

Biohit Oyj Stock Exchange Release November 20, 2013 at 8:30 a.m. local time
(EET) 



New B-share subscriptions, total 15.000 pcs, based on the company's stock
option program II 2013 approved by the Board of Directors of Biohit Oyj on
October 6, 2013, have been entered into the trade register today. The share
subscription price was three (3) euros per share. The nominal value of the
share, 2.550 euros, will be recorded in equity and the rest (42.450 euros) in
the invested unrestricted equity fund. 

After the subscriptions (15.000 shares), the number of all Biohit Oyj's shares
will rise into 13.810.593 shares (13.795.593) and B-shares will rise into
10.835.093 (10.820.093). The company's share capital will increase from
2,345,250.81 euros to 2,347,800.81 euros. 

The new shares will correspond to a percentage of 0.1% of the Biohit Oyj's
total number of shares and 0.02% of the share of voting rights after
registration. 

Biohit Oyj has applied for the listing of its new shares on the NASDAQ OMX
Helsinki in the same series as the company's existing shares. The new shares
will be listed on November 21, 2013. 



Additional information:

CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com



Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company established in
1988. Biohit's mission is “Innovating for Health”. The purpose of the company
is to take social responsibility and produce innovation, new technologies and
analysis systems for use in medicine, research institutions and industry,
helping to promote research and diagnostics and to improve people's quality of
life by preventing disease, human suffering and financial loss. We are
committed to social responsibility and it is our duty to spread knowledge about
the Group I human carcinogen, acetaldehyde, and innovate and develop the
marketing and availability of our products and services. Biohit is
headquartered in Helsinki, Finland and its subsidiaries are located in China,
Italy and the United Kingdom. Since 1999, Biohit's series B shares (BIOBV) have
been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.
www.biohithealthcare.com